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Abstract
Background: Finding efficacious tools to decrease and interrupt malaria transmission is essential to sustain the
gains in malaria control and contain the emergence of artemisinin resistance. Primaquine is effective against
Plasmodium falciparum gametocytes and recommended for treatment campaigns in (pre-)elimination settings.
Safety concerns preclude its use in endemic African countries with variable proportions of glucose-6-phosphate
dehydrogenase (G6PD)-deficient individuals. The efficacy of the current recommended dose needs to be evaluated,
particularly in individuals with an asymptomatic malaria infection.
Methods/design: This is a four-arm, open label, randomized controlled trial that aims to determine and compare
the effect of three different single doses of primaquine combined with dihydroartemisinin-piperaquine, an
artemisinin-based combination therapy, on gametocyte carriage in asymptomatic, malaria infected, G6PD-normal
individuals. Approximately 1,200 participants are enrolled and followed for 42 days, with the primary endpoint being
the prevalence of Plasmodium falciparum gametocyte carriage at day 7 of follow-up determined by quantitative
nucleic acid sequence based amplification assay. Direct membrane feeding experiments to determine infectiousness
to mosquitoes are conducted as a biological secondary endpoint.
Discussion: Sub-Saharan Africa, with a relatively high but poorly characterized G6PD prevalence, could potentially
benefit from the use of primaquine to further reduce or interrupt malaria transmission. However, G6PD screening
may not be feasible given the cost and difficulties in interpreting test results in terms of risk of haemolysis.
Because the haemolytic effect of primaquine is dose-dependent, determining the minimal gametocytocidal
and transmission-blocking dose of primaquine is extremely important to help address public health concerns over its
safety and validate the efficacy of lower than recommended dosages. By including infectiousness to mosquitoes, the
trial provides complementary evidence for the potential of the drug to interrupt transmission to mosquitoes.
Trial registration: ClinicalTrials.gov: NCT01838902 (12 April 2013).
Keywords: Malaria, Plasmodium falciparum, Asymptomatic infection, Gametocyte, Primaquine, Safety, Efficacy,
Elimination
* Correspondence: jokebe@mrc.gm
1Disease Control & Elimination Theme, Medical Research Council Unit, Fajara,
The Gambia
Full list of author information is available at the end of the article
TRIALS
© 2015 Okebe et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Okebe et al. Trials  (2015) 16:70 
DOI 10.1186/s13063-015-0597-1
Background
The scale-up of anti-malaria interventions, including
artemisinin-based combination therapy (ACT), and the
subsequent decline in many malaria indicators has
boosted prospects of local or regional malaria elimin-
ation [1]. However, it is evident that additional tools,
including drugs effective against sexual (gametocyte)
stages and programmes that are targeted at asymptom-
atic parasite carriage, would be needed if the goal of
interrupting Plasmodium falciparum malaria transmis-
sion were to be achieved.
A number of endemic countries, including some in
sub-Saharan Africa, have achieved substantial reductions
in their malaria burden [1,2] and are considering the
possibility of eliminating malaria within their borders.
Artemisinin derivatives are extremely effective against
both asexual and early-stage P. falciparum gametocytes
and less so against mature gametocytes [3,4]. Combining
ACTs with primaquine (PQ), an 8-aminoquinoline ef-
fective against mature gametocytes, targets all parasite
stages and thus can halt the transfer of gametocytes
from humans to mosquitoes. In this context, PQ could
play an essential role in interrupting transmission but
there are concerns, especially over its safety and efficacy,
that could preclude its large-scale use in these countries.
The optimal PQ dose used in combination with an
ACT against P. falciparum gametocytes has been the
subject of some discussion. Previously recommended by
the World Health Organization as a single 0.75 mg
base/kg, it was recently revised to 0.25 mg base/kg as
this dose was unlikely to result in serious toxicity, espe-
cially in individuals with any glucose-6-phosphate de-
hydrogenase (G6PD) deficiency variant, while retaining
its gametocytocidal effect [5]. Whereas the 0.75 mg
base/kg PQ dose had a variable impact on transmission
[6,7], the efficacy of the 0.25 mg base/kg has not been
evaluated in any recent trial.
A recently concluded dose-ranging trial of PQ plus
artemether-lumefantrine in children with uncomplicated
malaria showed that a 0.4 mg/kg dose was as efficacious
as the 0.75 mg/kg dose in clearing gametocytes [8]. The
trial excluded phenotypically G6PD-deficient individuals
by fluorescent spot test and observed no clinically
relevant haemolysis, although a statistically significant
haemolytic effect was observed in phenotypically G6PD-
sufficient but genotypically G6PD-deficient individuals
receiving 0.75 mg/kg or 0.4 mg/kg PQ [9].
The dynamics of gametocyte carriage may differ con-
siderably between symptomatic and asymptomatic infec-
tions and these differences in gametocyte dynamics may
explain why previous studies in Africa have reached dif-
ferent conclusions on the added value of PQ in symp-
tomatic and asymptomatic infections [7,10]. Although
the acute phase of clinical malaria attacks have been
associated with a subsequent wave of gametocytes that
may persist longer after treatment [11], asymptomatic
individuals typically have lower densities of both asexual
and sexual parasites yet potentially have more mature
gametocytes as a result of the long duration of asymptom-
atic parasite carriage [12]. Because asymptomatic infec-
tions typically comprise the majority of malaria infections
in populations [13], studies in asymptomatic parasite car-
riers are needed to provide complementary evidence for
the efficacy and safety of even lower PQ doses.
This study combines gametocyte carriage measured
using molecular detection methods [10,14] with a com-
plementary biological endpoint of gametocyte infectivity
in a sub-group of study subjects to assess the transmis-
sion blocking effect of PQ [15].
Trial objectives and endpoints
The trial aims to determine and compare the effect of
three different single doses of PQ combined with an
ACT, dihydroartemisinin-piperaquine (DHA-PPQ), on
gametocyte carriage in asymptomatic, malaria-infected,
G6PD-normal individuals. In addition, it will determine
and compare the effect of the above combinations on
change in haemoglobin concentration during follow-up,
infectiousness to mosquitoes, parasite clearance time
and cure rate.
The main trial endpoint is the prevalence of P. falcip-
arum gametocyte carriage at day 7 of follow-up deter-
mined by quantitative nucleic acid sequence based
amplification assay (QT-NASBA).
Other endpoints include: 1) the prevalence of P. falcip-
arum gametocyte carriage, determined by QT-NASBA,
during other follow-up visits; 2) change in haemoglobin
values between enrollment (day 0) and each day of follow-
up; 3) infectiousness to mosquitoes on day 7 determined
by direct membrane feeding assay (DMFA); 4) proportion
of participants with recurrent infections (polymerase chain
reaction adjusted and unadjusted) after day 7; and 5) the
prevalence of adverse events and serious adverse events.
Methods
Design
This is a four-arm, open label, randomized controlled
trial in which G6PD-normal asymptomatic Plasmodium
falciparum-infected individuals identified through popu-
lation screening are randomized to receive either a
complete course of DHA-PPQ alone (control) or a
course of DHA-PPQ plus one of three different doses of
PQ (intervention): 0.75 mg base/kg, 0.4 mg base/kg and
0.2 mg base/kg, given as a single dose.
Study area and participant selection
Participants are recruited from villages around the Medical
Research Council’s field stations in the Central and Upper
Okebe et al. Trials  (2015) 16:70 Page 2 of 7
River Regions in The Gambia. Malaria transmission in the
country is well described, and characterized by marked sea-
sonality with a peak between September and November
[16]. Participants are selected in a two-stage screening
process. An initial pre-screening is used to determine in-
fection (rapid antigen test kit) and establish a baseline
parasitaemia (microscopy). Individuals aged 1 year and
above with parasite density ≥20 parasites/μl are invited to
the base clinic the following day where, after a written in-
formed consent, they undergo screening for G6PD status
(N Dimopoulos SA, Greece), haemoglobin measurement
(Hemocue, Ängelholm, Sweden) and, if eligible, are en-
rolled (Figure 1). Infected but ineligible persons are treated
with a full course of artemether-lumefantrine. In addition,
those with haemoglobin counts <8 g/dl receive iron sup-
plements while G6PD-deficient individuals will be coun-
selled on their test results and provided with a notification
card indicating their G6PD status which they are advised
to present at clinics when seeking medical care.
Randomisation and blinding
Enrolment into the trial arms follows a randomisation
scheme in a 1:1:1:1 ratio using blocks of varying size to
ensure a balance in recruitment between the four
groups. A randomisation list, generated by the trial stat-
istician using Stata software version 13 (Stata Corp.
College Station, TX, USA), is sent to a physician not in-
volved in the trial who puts the codes for the allocation
groups into sequentially numbered, opaque envelopes.
The envelopes are opened by the clinic team only after
the potential participant meets the eligibility criteria.
This is an open-label trial; staff involved in clinical
care, including administering the trial drugs, are aware
of the assigned groups but those involved in sample pro-
cessing and data analysis are blinded.
Treatment and follow-up
All participants in the trial will receive a complete 3-day
course of DHA-PPQ based on body weight according to
Figure 1 DHA-PPQ, dihydroartemisinin-piperaquine; DMFA, direct membrane feeding assay; Hb, haemoglobin; G6PD, glucose-6-
phosphate dehydrogenase; PCR, polymerase chain reaction; PQ, primaquine; RDT, rapid diagnostic test.
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the manufacturer’s instructions. DHA-PPQ is available
as both paediatric (dihydroartemisinin 20 mg/pipera-
quine 160 mg) and adult (dihydroartemisinin 40 mg/
piperaquine 320 mg) formulations. Participants in the
three intervention arms are randomized to receive a sin-
gle 0.75 mg/kg, 0.40 mg/kg or 0.20 mg/kg dose of PQ
base on day 2 with the third dose of DHA-PPQ. Each
tablet of PQ contains 15 mg base and, to ensure the ac-
curacy of doses <15 mg, the tablet will be reconstituted
in 15 ml water to achieve a 1 mg/ml concentration and
the required dose dispensed using a sterile syringe. A
nurse directly observes all treatments and treatment
may be repeated once if a participant vomits any of the
drugs within 30 minutes of being administered.
Each participant attends eight scheduled follow-up
visits on days 3, 7, 10, 14, 21, 28, 35, and 42 for clinical
evaluation and blood sampling. Blood samples from a
finger prick are collected for gametocyte (QT-NASBA)
and asexual parasite clearance (microscopy and polymer-
ase chain reaction) and haemoglobin measurement.
Additional tests may be requested during unscheduled
visits to the clinic (Table 1). Thick blood films stained
with 10% Giemsa for 10 minutes are examined under
1000-fold magnification by trained microscopists. Asex-
ual parasite density is determined by counting the num-
ber of asexual parasites per white blood cell (WBC) until
500 WBCs have been counted (assuming a mean WBC
count of 8,000/μl) and results presented as parasites/μl.
Quantitative nucleic acid sequence based amplification
assay
The primary endpoint of the trial is the prevalence of ga-
metocytes measured by molecular methods on day 7 of
follow-up. The detection and quantification of gameto-
cytes is by real-time QT-NASBA which is based on
stage-specific gene expression of Pfs25 mRNA by para-
sites. QT-NASBA is a high throughput technique suited
to detecting mature gametocytes with a sensitivity of
0.01 to 0.1 gametocytes/μl blood [17]. It is based on the
activities of three enzymes: Reverse transcriptase, T7
RNA polymerase and RNase H and target-specific
forward and reverse primers, which includes a T7 poly-
merase promoter sequence, for continuous and direct
amplification of RNA molecules in a single mixture at
an isothermal temperature of 41°C. Real-time gametocyte
detection and quantification is by a fluorescent-labelled
molecular beacon with a sequence complementary to those
of amplified anti-sense RNA molecules.
RNA is extracted manually from 50 μl of blood stored
in RNAlater using commercial lysis buffers (Severn
Biotech, Kidderminster, Worcestershire, UK) and previ-
ously described methods that involve nuclease inactiva-
tion and nucleic acid binding [18]. Gametocyte density
is calculated in relation to the standard gametocyte stage
V dilution series using the time point of amplification at
which the fluorescence detecting target amplicons exceed
the mean fluorescence of three negative controls + 20
standard deviations [17]. Standard curves for density quan-
tification are generated using trend lines of known
quantities of gametocytes from laboratory-cultured NF54
parasite strains.
Direct membrane feeding assay
To measure biological evidence of gametocyte clearance,
a subset of 100 participants from each arm will be ran-
domly selected for direct membrane feeding experiments
on day 7 using a published protocol [19]. In summary,
3 ml of blood are collected from the participant’s arm
and 500 μl is added to two glass feeders and fed to about
100 locally reared 4- to 5-day-old female Anopheles
Table 1 Trial activity on scheduled visit days
Day −1 0 1 2 3 7 10 14 21 28 35 42
Village screening (RDT+ slide) X
Informed consent for the trial X
G6PD test X
Clinical review (history and examination) X X X X X X X X X
Temperature, pulse X X X X X X X X X X
Weight X
Thick blood film X X X X X X X X X X X
Haemoglobin, PCR (filter paper) X X X X X X X X X
Gametocytaemia (QT-NASBA) X X X X X X X
Adverse events X X X X X X X X X X X
Treatment X X X
Direct membrane feeding assay X
G6PD, glucose-6-phosphate dehydrogenase; PCR, polymerase chain reaction; QT-NASBA, quantitative nucleic acid sequence based amplification assay; RDT, rapid
diagnostic test.
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gambiae sensu stricto mosquitoes through an artificial
membrane. The setup is maintained at 37°C by a
temperature controlled water bath and, after 15 minutes
of feeding, fully fed mosquitoes are transferred into a
holding cage maintained at 27 to 29°C and sustained on
5% glucose for 7 days while partially fed and unfed ones
are destroyed. Mosquitoes that survive to this period are
dissected in 0.5% mercurochrome, and their midguts ex-
amined for oocyst prevalence and density. The propor-
tion of infected mosquitoes, the number of infected
mosquitoes divided by the total number of examined
mosquitoes, and the density of oocysts in infected mos-
quitoes is presented.
Sample size considerations
The sample size was calculated to detect a difference in
gametocyte prevalence on day 7 after treatment, between
the control (DHA-PPQ only) and 0.75 mg/kg PQ arm,
and between this and lower doses of PQ (0.4 mg/kg and
0.2 mg/kg). Two hypotheses underscore the sample size
calculation: 1) treatment with PQ (any dose) and DHA-
PPQ results in significantly lower gametocyte carriage
compared to treatment with DHA-PPQ alone; and 2) a
single dose of 0.4 mg base/kg or 0.2 mg base/kg PQ ad-
ministered with the last dose of DHA-PPQ has similar
gametocytocidal efficacy as a single 0.75 mg base/kg
dose.
For the first hypothesis, the underlying assumption is
that, although a substantial proportion of asymptomatic
carriers also carry gametocytes [20], treatment with an
ACT alone would reduce gametocyte prevalence on day
7 to around 18%, and the addition of PQ at 0.75 mg/kg
will further reduce the prevalence by 50% (that is,
to 9%). A sample size of 300 participants per arm would
have 90% power to detect this difference, at the 5% sig-
nificance level, allowing for 10% of enrolees being non-
compliant or lost to follow-up.
In the second hypothesis, assuming a prevalence of 9%
in the standard PQ arm, 300 participants would be suffi-
cient, with 90% power, to detect a confidence interval
around the prevalence in the lower dose PQ arm below
16% and 80% power to detect that this confidence inter-
val is entirely below 15%.
Statistical analysis plan
Analysis of efficacy will be on the basis of intention-to-
treat. Gametocyte densities will be compared between
treatment groups using one-way analysis of variance on
log-transformed gametocyte densities; gametocyte car-
riage during follow-up will be estimated by calculating
for each arm the area under the curve (AUC) of both
the gametocyte density and gametocyte prevalence
against time. The AUC between treatment groups will be
compared using non-parametric tests. The Kaplan-Meier
estimator will be used to compare gametocyte clearance
times between study arms for individuals who are gam-
etocyte positive by QT-NASBA at enrolment.
For the non-inferiority comparison between the PQ
arms, the 95% confidence around the gametocyte preva-
lence in the PQ 0.4/0.2 mg/kg arms at day 7 will be
compared to the non-inferiority limit determined by the
prevalence in the PQ 0.75 mg/kg arm and delta.
For the DMFA, the proportion of infectious individ-
uals will be compared between arms using chi-squared
statistics. The proportion of infected mosquitoes will be
compared between groups using mixed models to ac-
count for clustering within cages fed on blood from the
same individual.
Data entry and validation
Clinical data will be captured from pre-tested med-
ical records and relevant fields entered onto an elec-
tronic case report form base created in Openclinica
(OpenClinica LLC, Waltham, Ma, USA). Data will be
single entered with source-data verification done for each
entry. Laboratory-generated (DMFA and QT-NASBA)
data will be double entered onto a Microsoft Access data-
base (Microsoft Corp., Richmond, WA, USA) and linked
to the clinical data after validation.
Ethical approval
The trial was approved by The Gambia Government/
MRC Joint Ethics Committee (SCC 1321) on 13 March
2013.
Discussion
Local and regional malaria elimination is gaining accept-
ance as a means to sustain the gains made in reducing
the malaria burden and limiting/preventing the spread
of artemisinin resistance. However, achieving these
objectives would require a fresh perspective on the ne-
cessary tools and applications.
Although individuals with clinical disease due to asex-
ual P. falciparum infection also carry gametocytes in
variable amounts [21], asymptomatic infections are be-
lieved to play an important role across all levels of mal-
aria transmission and therefore targeting only clinical
cases would miss the large human reservoir of infection
[12]. This concept is supported by evidence from empir-
ical studies and mathematical models [22,23], and the
combination of an ACT with PQ is recommended in
places where (pre-)elimination is being considered [24].
In asymptomatic infections, parasite density (both
asexual forms and gametocytes) are much lower than in
clinical cases. However, one model estimate predicts that
these low-density infections, even when undetectable by
microscopy, may still be infectious to mosquitoes [25].
Parasite densities are estimated by counting parasites
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against a given number of WBCs, usually 200 WBCs,
and then assuming 8,000 WBCs per μl [26]. Neverthe-
less, when parasite densities are <100/μl, a higher sensi-
tivity may be needed [26] and this can be done by
increasing the number of WBCs against which the
number of parasites are counted, usually 500. Given the
short time available to recruit participants into the trial,
counting parasites against 500 WBCs is extremely
challenging.
As the trial aims to determine the lowest gametocyto-
cidal PQ dose, it was necessary to include individuals
with microscopically detectable infections. The threshold
of >20 parasites/μl as an inclusion criterion was chosen
as a proxy to increase the likelihood for gametocytaemia
[11]. Including carriers of submicroscopic infection
would not have been feasible given the need to deter-
mine their eligibility in a relatively short time. Blood
slides can be re-read later and the number of WBCs per
slide increased for higher sensitivity [27].
The potential for inducing haemolysis is probably the
main reservation for the widespread use of PQ. In sub-
Saharan Africa, the overall prevalence of G6PD defi-
ciency is considered to be high [28]. A recent survey in
The Gambia showed that the prevalence of the 202A-
mutation, reportedly the most common in sub-Saharan
Africa, was 1.8% while the phenotype prevalence was
6.4% overall; 7.8% in males and 4.9% in females [29].
Such low numbers may suggest a low risk but does not
eliminate it entirely as individuals with “normal” G6PD
status have developed haemolysis [30]. A trial to evaluate
the tolerability and safety of increasing doses of PQ in
combination with an ACT in G6PD-deficient males with
an asymptomatic P. falciparum malaria infection has re-
cently been initiated (NCT02174900) and the results
would complement those of this trial.
As the haemolytic effect of PQ is dose-dependent, de-
termining the minimal gametocytocidal dose is consid-
ered an extremely important first step in addressing
public health concerns related to the safety and efficacy
of PQ as summarized in a recent systematic review [31].
Since the initial trial protocol was developed, a single
0.25 mg base/kg dose of PQ combined with an ACT is
now recommended as sufficiently safe and gametocytoci-
dal to be used without screening for G6PD deficiency
[5]. However, the evidence for this dose may be consid-
ered inadequate by contemporary standards.
The optimization of the PQ dosing regimen therefore
represents an important knowledge gap and research
priority [32] as it provides a “new/old” tool for malaria
(pre-)elimination. The recently concluded dose-finding
trial in children aged 1 to 10 years with uncomplicated
falciparum malaria and normal G6PD enzyme function
provides encouraging complementary information to
support research in G6PD-deficient individuals [8]. Also,
the haematological consequences may be less manifest
in asymptomatic carriers as the malaria-related haemoly-
sis would be less pronounced.
By evaluating infectiousness to mosquitoes, the trial
contributes a biological endpoint - the evidence for
transmission reduction or complete transmission block-
ade to mosquitoes that is ultimately relevant for public
health policy making.
Trial status
Recruitment started in August 2013 with trial results
expected in December 2015.
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